cerebrolysin: a porcine brain-derived peptide mixture for stroke and dementia

cerebrolysin is a porcine brain-derived preparation of low-molecular-weight peptides and free amino acids, manufactured by enzymatic breakdown of purified pig brain protein. it is given as an intravenous infusion and is licensed in roughly 50 countries, primarily in central and eastern Europe, Russia, China, and several Asian countries, for acute ischaemic stroke, vascular dementia, Alzheimer disease, and traumatic brain injury. it is not approved by the US FDA. the most recent Cochrane review of cerebrolysin for acute ischaemic stroke did not find convincing evidence of benefit on death or dependency.

what is cerebrolysin?

cerebrolysin is best described as a biologic extract rather than a defined peptide. its manufacturer (Ever Neuro Pharma in Austria, originally developed by EBEWE) makes it by controlled proteolytic breakdown of purified porcine brain protein, yielding a mixture of free amino acids (around 85 percent by mass) and small peptides under about 10 kilodaltons (around 15 percent).

unlike a defined research peptide such as BPC-157 or an approved single-sequence drug such as tesamorelin, the active substance of cerebrolysin is not a single molecule. the manufacturer characterises it as a neuropeptide preparation with neurotrophic and neuroprotective properties, and ascribes activity to small peptides within the mixture that share sequence features with endogenous neurotrophic factors such as ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), and nerve growth factor (NGF) [1]. because the mixture is complex, batch-to-batch consistency and the identity of individual active peptides have been ongoing topics of regulatory scrutiny.

cerebrolysin is administered as an intravenous infusion or slow injection in a clinical setting, not by patients at home. it is delivered as multi-day or multi-week courses, repeated over time in many of its approved indications.

how does it work?

the proposed mechanism is multimodal neurotrophic and neuroprotective signalling. preclinical studies have reported reduced excitotoxicity, modulation of calcium-mediated cell death pathways, support of synaptic plasticity, and effects on neurogenesis, behaving in animal models as a small-molecule mimic of endogenous neurotrophic factors.

in rodent and cell-culture models the mixture has been reported to reduce glutamate-driven excitotoxicity, attenuate caspase-3 activation in apoptotic pathways, and support the survival of cortical and hippocampal neurons after ischaemic or traumatic insults [1]. in chronic neurodegenerative models, including transgenic Alzheimer-disease mouse lines, cerebrolysin has been described as modulating amyloid processing and improving synaptic and behavioural endpoints.

the honest framing is: the proposed mechanism is a plausible aggregate effect of a peptide mixture acting like a low-grade cocktail of endogenous neurotrophic signalling. that is mechanistically interesting and also harder to characterise rigorously than a defined single-receptor agonist.

what does the evidence show?

cerebrolysin has been studied in dozens of randomised controlled trials across stroke, dementia, and TBI, with most pivotal data published between roughly 2005 and 2020. results are heterogeneous, and independent systematic reviews have been more cautious than the original trial reports.

in acute ischaemic stroke, the CASTA trial by Heiss and colleagues in Stroke in 2012 randomised 1,070 patients across China, Hong Kong, Korea, and Myanmar to cerebrolysin 30 mL intravenously for 10 days versus placebo, on top of aspirin, within 12 hours of stroke onset. the primary combined endpoint at day 90 (NIHSS, modified Rankin scale, Barthel index) was not significantly different between groups in the overall population, although a post-hoc subgroup with more severe baseline stroke (NIHSS over 12) favoured cerebrolysin [2]. the CARS-I trial by Muresanu and colleagues in Stroke in 2016 was a smaller (n=208) RCT that paired cerebrolysin with standardised early rehabilitation for 21 days and reported a positive primary endpoint on upper-extremity motor function at day 90 [3].

the 2023 Cochrane review of cerebrolysin for acute ischaemic stroke by Ziganshina and colleagues pooled the available randomised data and concluded that there is no convincing evidence of benefit on death or dependency, and that the available evidence shows moderate-certainty increase in non-fatal serious adverse events with cerebrolysin compared with placebo [4]. a separate 2017 meta-analysis of the CARS programme suggested motor-function benefits in patients receiving early rehabilitation [5]. these two reads of the same general literature illustrate why cerebrolysin remains contested.

in dementia, Alvarez and colleagues in the European Journal of Neurology in 2011 reported a dosage-finding RCT in moderate to moderately severe Alzheimer disease showing significant global clinical improvement with cerebrolysin across three dosages versus placebo at 24 weeks, with cognition improvements at some endpoints and less consistent effects on activities of daily living [6]. Cochrane and other systematic reviews of cerebrolysin in vascular dementia have generally rated the evidence as low quality and have not endorsed routine use [7]. cerebrolysin has therefore not entered major Western dementia or stroke guidelines, even though it has decades of registered clinical use in other regions.

regulatory status

cerebrolysin is approved and marketed in roughly 50 countries, with strong presence in Russia, China, central and eastern Europe (including Austria where it is manufactured), and several Asian countries. it is not approved by the FDA in the US and not licensed by the MHRA in the UK. importing it for personal use is generally a regulatory grey zone in jurisdictions where it is not registered.

the manufacturer's registration history is European: cerebrolysin originated with EBEWE in Austria and is now produced by Ever Neuro Pharma. national licensures vary in indication but commonly include acute ischaemic stroke, vascular dementia, Alzheimer disease, and traumatic brain injury. in the US, the FDA has not approved cerebrolysin for any indication, and no open IND-stage Phase 3 programme has progressed to approval in either the US or the EU centralised system.

cerebrolysin is not on the World Anti-Doping Agency prohibited list as a specific entry, but anti-doping authorities treat undeclared biologic extracts cautiously and athletes should consult their federation before any use. because cerebrolysin is a biological extract, importation, compounding, and re-labelling carry both regulatory and contamination concerns relative to a defined single-sequence peptide.

safety profile

the most consistently reported adverse events are mild and short-lived: injection-site reactions, sweating, dizziness, headache, and occasional agitation. rare hypersensitivity reactions consistent with a biologic preparation have been described. the most important safety signal in the literature is the moderate-certainty increase in non-fatal serious adverse events identified in the 2023 Cochrane review of stroke trials.

across the pivotal stroke and dementia trials and the manufacturer's pharmacovigilance program, cerebrolysin has generally been described as well tolerated. routine clinical use in approving countries spans decades. the 2023 Cochrane review nevertheless identified a moderate-certainty increase in non-fatal serious adverse events when pooling cerebrolysin against placebo in acute ischaemic stroke trials, which is a real signal that the clinical community has not fully reconciled with the more reassuring single-trial safety statements [4].

as a porcine-derived biological extract, cerebrolysin also requires confidence in source-control and viral-inactivation steps that are routine for licensed biologics in approving jurisdictions and harder to verify for grey-market sourced product.

where it fits in peptide therapy

cerebrolysin sits in a unique category: it is a registered drug in roughly 50 countries, has a large RCT dataset, and is structurally a biologic peptide mixture rather than a single sequence. that places it apart from both the FDA-approved single-peptide drugs and the unregistered research peptides that fill most peptide-therapy conversations.

within neuroactive peptides, the natural comparisons are DSIP, selank, and semax, all of which are short, defined peptides with smaller RCT footprints than cerebrolysin and limited or no FDA approval. cerebrolysin's much larger trial dataset and its 50-country registration make it the most clinically validated member of that family, even with the Cochrane caveats.

within neuroprotective and brain-injury settings, no FDA-approved peptide drug currently competes with cerebrolysin's positioning. comparisons to small molecules such as edaravone (approved in Japan and the US for ALS in a related class) are illustrative, not direct.

for a structured introduction to the broader peptide landscape and to where biologic extracts sit relative to defined synthetic peptides, the free peptide basics module is the starting point, and the natural vs synthetic peptides blog covers the conceptual distinction that cerebrolysin makes concrete.